Intrauterine growth restriction (IUGR) is the failure of the fetus to achieve his/her intrinsic growth potential, due to anatomical and/or functional disorders and diseases in the feto-placental-maternal unit. IUGR results in significant perinatal and long-term complications, including development of insulin resistance/metabolic syndrome in adulthood.
4 unrelated to age, sex and ethnic origin, and occurs independently of current weight and level of exercise [6, 7] .
The thrifty phenotype hypothesis proposes that the association between poor fetal growth and subsequent development of type 2 diabetes/metabolic syndrome results from the effects of poor intrauterine nutrition, producing permanent changes in glucose-insulin metabolism [8] . These changes include reduced capacity for insulin secretion and insulin resistance [8] .
In this respect, alterations in fetal nutrition may result in developmental adaptations that permanently change the physiology and metabolism of the offspring, thereby predisposing individuals to metabolic, endocrine and cardiovascular disorders [8, 9] . This phenomenon, termed "fetal programming", has led to the "fetal origins of adult disease" theory [10, 11] .
The fetus adapts to an adverse intrauterine milieu by optimizing the use of a reduced nutrient supply to ensure survival. Therefore, blood flow redistribution in favour of vital organs and changes in the production of fetal and placental hormones, controlling fetal growth, take place [10] . Although this topic has been controversial, recent epidemiological, clinical and animal studies support the theory of the "developmental origins of adult disease" [12] [13] [14] .
On the other hand, the fetal insulin hypothesis proposes that genetically determined insulin resistance could result in low insulin-mediated fetal growth and insulin resistance in childhood and adulthood [15] . Insulin is one of the major growth factors in fetal life, and monogenic disorders that affect fetal insulin secretion and resistance also affect fetal growth [16, 17] . However, such mutations are rare, and no analogous common allelic variation has been discovered.
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Mechanisms
Underlying molecular and cellular mechanisms of metabolic programming are not clear, but may include reprogramming of the hypothalamic-pituitary-adrenal axis and insulin-signaling pathways [18] . In many instances, the metabolic and other disorders associated with IUGR have an endocrine origin and are accompanied by changes in hormone bioavailability in adulthood [19] . Abnormalities in the circulating concentrations of insulin, catecholamines, cortisol, growth hormone (GH) and insulinlike growth factors (IGFs) have been observed in children and adults being born IUGR [18, 20] . These observations have led to the hypothesis that adult disease arises in utero, in part, as a result of changes in the development of key endocrine axes during suboptimal intrauterine conditions [19] . Thus, a thrifty phenotype results to increased sensitivity of the peripheral tissues to metabolic hormones, such as glucocorticoids and insulin, a condition that ensures survival and maximizes growth and fuel deposition, given that nutritional conditions improve after birth [19] . If postnatal nutrient availability is greater than prenatally predicted, enhanced postnatal growth and fat deposition will occur. In turn, this increased adiposity will lead to adult insulin resistance [21] . Certainly, the risk of developing adult metabolic syndrome is greatest, when poor prenatal growth is coupled with rapid catch-up growth during childhood [22] .
In this respect, a study conducted in a Finish cohort in 1999 revealed a possible link between catch-up growth and insulin resistance, reporting that IUGR individuals experiencing rapid catch-up growth had the highest mortality from coronary heart disease [23] . Since then many researchers have illustrated this link in children and young adults born IUGR [24] [25] [26] . Furthermore, the work of Colle et al. first established that glucose-stimulated plasma insulin concentrations in infants and 6 children born small-for-gestational-age (SGA) were higher during catch-up growth [27] . This and other studies have emphasized that insulin resistance is an early manifestation of the mechanisms by which catch-up growth may predispose to adult disease [26, 28] .
THE ROLE OF ADIPOSE TISSUE
A growing body of evidence recently suggests that the adipose tissue may also play a major role in linking poor fetal growth to subsequent development of adult diseases Since the discovery of adipocyte-derived hormones, collectively called adipocytokines, the adipose tissue is no longer considered an inactive fat store tissue, Given the importance of adipose tissue and its hormones in fetal growth and maturation for both survival at birth and overall health, it is of interest to explore the physiology of adipocytokines in early life, as well as those factors that may perturb the balance of these hormones in the IUGR state with pathological consequences in terms of confining an increased risk for adult disease. Leptin seems to be a critical factor for overall fetal development [46, 47] . The hormone is produced in both maternal and fetal adipose tissues and the placenta [46, 48] , while its receptors are abundant in the uterine endometrium, trophoblast and the fetus [49] . Fetal adipose tissue is an important source of leptin and fetal leptin levels are strongly related to birth weight and fetal adiposity [37, [50] [51] [52] [53] . Furthermore, a Recent data suggest that prenatal undernutrition associated with IUGR can shape future susceptibility to obesity, obesity-related disorders and osteoporosis through alterations in the regulation of leptin secretion and sensitivity [45, 46, 54, 55] . Thus, leptin may play a role in the control of substrate utilization and in the maintenance and functional characteristics of fat mass before birth, producing permanent changes, concerning adiposity and body composition in adult life [55, 56] . Moreover, accumulating evidence indicates that the risk of osteoporosis may also be determined by factors acting on intrauterine bone development via alterations in leptin dynamics [54, 57] .
Leptin in IUGR
Several studies demonstrated lower circulating leptin concentrations in IUGR neonates at birth, due to reduced fat mass [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] and/or decreased placental production [73] [74] [75] . In some of these studies, fetal leptin levels per kilogram of fetal weight, as well as fetal leptin levels before 34 weeks of gestation, were not significantly different in IUGR, indicating that leptin secretion is mainly associated with adipose tissue accumulation [61] [62] [63] [64] . However, other investigators suggested that low fetal leptin levels in IUGR are associated with reduced placental production, since leptin levels dramatically decrease shortly after birth [73] [74] [75] . Nevertheless, these reduced fetal concentrations increase and become higher in IUGR infants, children and adults, compared to normal birth weight controls, regardless of body mass index (BMI) [76] [77] [78] , suggesting either an adaptive leptin resistance beneficial for catch-up growth, or an adipocyte dysfunction associated with IUGR [76] .
Therefore, leptin may represent one of the mechanisms whereby intrauterine factors, Taken together, these data indicate that intrauterine exposure to either intrauterine hypo-or hyperleptinemia may programme central or peripheral energy-regulating systems, predisposing to postnatal obesity. In addition to regulating body metabolism, adiponectin is also produced within the intrauterine environment [52, [103] [104] [105] . The findings that adiponectin is present in cord blood [103] , positively correlates with birth-weight [52, 104] and is highly produced by both the placenta and the fetus [52, 105] , suggest that this adipocytokine may play a key role in fetal growth, probably enhancing the growth-promoting effect of insulin through its insulin-sensitizing action [52] . The high fetal adiponectin concentrations may be attributed to lack of negative feedback on adiponectin production, resulting from lack of adipocyte hypertrophy, low percentage of body fat, or a different distribution of neonatal fat depots [106, 107] . On the contrary, other investigators failed to demonstrate a relation between fetal adiponectin and birth weight [103] .
Adiponectin in IUGR
Given the significance of glucose and insulin in fetal growth [108] and the fundamental role of adiponectin in insulin metabolism [99, 100] , it is reasonable to assume that adiponectin may play a regulatory role in IUGR. A number of studies [71, 103, 106] , including our published data [80] , demonstrated lack of significant differences in fetal adiponectin concentrations between IUGR cases and AGA controls, probably due to lack of insulin resistance, present in early life. However, [39, 125, 126] . This finding was attributed to the state of undernutrition of these fetuses and a role for ghrelin in fetal adaptation to intrauterine malnutrition has been proposed [125, 126] .
Furthermore, fasting is known to stimulate GH release in infants with IUGR, who characteristically show elevated basal levels of GH [127] . Therefore, the augmented ghrelin concentrations in IUGR may consequently lead to elevated GH concentrations, as ghrelin has a potent GH-releasing activity [122] . Eventually, the higher ghrelin concentrations may serve to stimulate appetite, resulting in higher nutritional intake by the IUGR neonate after birth [126] . In agreement, both higher ghrelin levels and hyperphagia have postnatally been demonstrated in human and animal IUGR subjects, suggesting a role for ghrelin in postnatal catch-up growth [91, 128, 129] .
Tumor necrosis factor-alpha (TNF-a) and Interleukin-6 (IL-6) in IUGR Adipose tissue monocytes and macrophages produce inflammatory cytokines, such as TNF-a and IL-6, which may eventually lead to insulin resistance [130] . TNF-a and IL-6 are also produced by the placenta during pregnancy [131] , but very few and contradictory data exist in the literature, regarding the IUGR state. In this respect, reduced [132, 133] and also increased [134] fetal IL-6 levels have been documented in IUGR, possibly due to impaired trophoblast function and severe placental insufficiency in the former and to hypoxia and/or nutrient deficiency in the latter, supporting the hypothesis that IL-6 may be related to fetal growth in the fetomaternal interface. On the other hand, normal [132] and also decreased [135] fetal TNF-a levels have been demonstrated, proposing a role for TNF-a in the pathogenesis of IUGR. On the other hand, upregulation of TNF-a has been postulated to be a survival mechanism in the IUGR fetus, by inducing muscle insulin resistance, thus enabling glucose to be spared for brain metabolism [136] . It would be reasonable to suggest that perinatal stressors could lead to reprogramming of TNF-a regulation with overproduction that persists in postnatal life and causes insulin resistance. However, low TNF-a levels have been reported in SGA insulin-resistant children [137] . The authors speculate that down-regulation of TNF-a may be one of the mechanisms leading to insulin resistance in these subjects [137] . Furthermore, Casano-Sancho et al. reported that SGA children show increased frequency of the TNF-308G allele, that is associated with prenatal growth and postnatal insulin resistance [138] . This polymorphism may be implicated in the metabolic abnormalities that characterize SGA children [138] .
Nevertheless, IUGR is a heterogeneous state, including cases of fetal malformations, infections or placental insufficiency due to preeclampsia [1] . This fact, as well as differences in disease severity, might explain the contradictory results of the above studies.
Novel adipocytokines in IUGR
Given the documented importance of fetal adipose tissue and its hormones in fetal growth for both survival at birth and overall health, a number of very recent studies from our group [139] [140] [141] [142] [143] investigated the implication of newly discovered adiposederived hormones in fetal growth and IUGR, in terms of confining their potential association with an increased risk for adult disease.
Specifically, resistin, a newly discovered metabolic hormone secreted by human adipocytes and mononuclear cells, has been postulated to play important roles in regulating energy homeostasis [144] . Resistin impairs glucose metabolism and opposes the action of insulin in peripheral tissues [144, 145] . Higher serum resistin concentrations have been documented in obese subjects and resistin has been suggested to link obesity to insulin resistance [144, 145] . Furthermore, resistin is expressed in the human placenta and has been postulated to play a role in regulating energy metabolism in pregnancy [146, 147] . Recent reports, including our data [40, 139, 148] , have also demonstrated the presence of markedly high concentrations of resistin in umbilical plasma samples, indicating the potential role of this adipocytokine in controlling fetal energy homeostasis and affecting deposition of adipose tissue in utero.
Apelin is a novel bioactive peptide, identified as the endogenous ligand of the orphan G protein-coupled receptor, APJ [149] . Ιt has a widespread pattern of expression in human tissues and it is produced in several organs, including brain, lung, lactating breast and gastrointestinal tract [150] . Embryonic expression studies indicated that apelin is an angiogenic factor required for normal blood vessel growth and endothelial
Page 15 of 46 cell proliferation [151] . Moreover, the presence of apelin has been documented in human placental tissue, indicating an important role of this peptide in fetal development [152] . We recently demonstrated the presence of markedly high concentrations of apelin in umbilical plasma samples and suggested a potential role of this peptide in intrauterine growth [140] . Furthermore, apelin has been identified as a novel adipocytokine, secreted in substantial amounts by adipose tissue in a regulated manner [153] . In this respect, apelin is up-regulated by obesity and hyperinsulinemia in both humans and mice [153] . Thus, current research focuses on the potential link of apelin with obesity-associated insulin resistance [154] .
Recent studies from our group, investigating resistin and apelin concentrations in the IUGR state, demonstrated lack of differences in resistin and apelin concentrations between IUGR cases and AGA controls and lack of correlation between resistin, as well as apelin with insulin concentrations, as well as customized centiles (adjusted birth-weights) of the studied infants [139, 140] . We speculate that resistin and apelin may not be directly involved in the regulation of insulin sensitivity and adipogenesis in the perinatal period [139, 140] .
Visfatin, a 52-kD protein, has been recently identified as a visceral fat-specific adipocytokine [155] , probably linking the expansion of adipose depot to insulin resistance [156] . Visfatin was initially thought to be upregulated in obesity and in states of insulin resistance, while exerting insulin mimetic effects in various tissues
[155]. However, subsequent studies have generated disparate findings with regard to the role of visfatin in obesity and insulin resistance and the pathophysiological role of visfatin in humans remains controversial and largely unknown [157, 158] .
Visfatin is identical to pre-B-cell colony enhancing factor (PBEF), a cytokine involved in B-cell precursor maturation [155] . The PBEF protein is immunolocalized in both normal and infected human fetal membranes and is significantly up-regulated by labor [159] . Moreover, data of a recent study from our group indicate that visfatin is present in cord blood in substantial amounts, probably due to placental production [141, 142] .
Of particular interest are our results regarding visfatin concentrations in the IUGR state [143] . In this respect, higher visfatin concentrations were found in IUGR neonates compared to AGA counterparts, probably due to increased visceral adiposity or altered fetal development of adiposity in IUGR subjects [29, 31] , which may predispose to the later development of insulin resistance [143] . We hypothesize that higher visfatin concentrations in IUGR could probably serve as an early marker with prognostic value for the later development of the metabolic syndrome in this population [143] . By contrast, a recent study concluded that visfatin may not be involved in the disturbed glucose metabolism of the IUGR rat offspring and may only represent a marker of fat accumulation [86]. Table 1 summarizes the results of major articles investigating circulating concentrations of adipocytokines in IUGR versus AGA subjects.
CONCLUSIONS
Differential regulation of adipocytokines in the IUGR state may be predictive of adult disease occurrence. The inability to undertake longitudinal studies from early to adult life makes it difficult to directly evaluate the existence of such associations.
Nevertheless, a role of leptin, adiponectin, ghrelin and visfatin appears likely, although at this stage, it is difficult to document whether this is a major regulating role or a reflection of other more critical endocrine and growth-related processes. Most studies indicated lower leptin, normal or lower adiponectin and higher ghrelin, as well 
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